Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most high-level statements about indication and class mechanism are not directly verifiable from the provided label excerpts, and multiple specific pharmacokinetic/protein-binding and warfarin/digoxin displacement claims are not supported by the supplied labeling. Generic availability and patent expiration are also not supported by the provided label excerpts.
Category Scores
Accurate Statements
Statins work by inhibiting the enzyme HMG-CoA reductase.
SECTION 12.1 — "LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase".
Unsupported Statements
Lipitor (atorvastatin) is a cholesterol-lowering medication used to treat high cholesterol.
The provided excerpts include indications for hyperlipidemia, but do not explicitly state the phrase "cholesterol-lowering medication" or "treat high cholesterol." Indication content is present, but this exact framing is not directly supported.
Lipitor (atorvastatin) is used to reduce the risk of cardiovascular disease.
While SECTION 1.1/1.2 lists reductions in MI/stroke/revascularization/angina, the provided excerpts do not explicitly use the term "cardiovascular disease" as a single risk endpoint.
Atorvastatin belongs to the class of statins.
The label excerpt does not explicitly state "atorvastatin is a statin," though it refers to "HMG-CoA reductase inhibitors (statins)" in SECTION 2.4/7.
HMG-CoA reductase plays a central role in cholesterol production in the liver.
SECTION 12.1 describes inhibition of HMG-CoA reductase and that it is a precursor of sterols including cholesterol, but the provided excerpts do not specify "in the liver".
Atorvastatin is approximately 95% plasma protein bound.
No plasma protein binding percentage is provided in the supplied excerpts.
Atorvastatin is primarily bound to albumin.
No statement about albumin as the primary binding protein is provided in the supplied excerpts.
High protein binding can impact the way other medications are transported in the body.
General pharmacology statement not provided in the supplied label excerpts.
Protein-bound drugs can displace and compete with other medications for binding sites on plasma proteins.
No such general mechanism is stated in the provided label excerpts.
Atorvastatin significantly displaces warfarin from plasma protein binding sites.
No warfarin/protein displacement claim is provided in the supplied excerpts (only generic interaction risks with certain drug classes/strong CYP3A4 inhibitors are shown).
Atorvastatin displacement of warfarin from plasma protein binding sites potentially increases the risk of bleeding in patients taking these medications concurrently.
No warfarin-specific protein displacement or bleeding-risk statement is included in the supplied excerpts.
Atorvastatin displaces digoxin from plasma protein binding sites.
No digoxin/protein displacement claim is provided in the supplied excerpts.
Atorvastatin displacement of digoxin from plasma protein binding sites can increase the risk of toxicity in patients taking these medications together.
No digoxin-specific protein displacement or toxicity-risk statement is included in the supplied excerpts.
The patent for Lipitor expired in 2015.
Patent status is not addressed in the provided label excerpts.
Lipitor is available in generic form.
Availability of generic products is not addressed in the provided label excerpts.
Contradictions
Important Omissions
For the cardiovascular risk reduction claim, the label excerpts specify particular endpoints (e.g., myocardial infarction, stroke, revascularization, angina; and in diabetes subgroup MI and stroke). The AI claim is broader and omits those specific labeled endpoints.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported warfarin/digoxin protein-displacement and bleeding/toxicity linkage claims could mislead about interaction mechanisms and risk; however, the provided excerpts do include other statin interaction warnings (e.g., CYP3A4 inhibitors) which were not addressed by these specific unsupported claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple specific mechanistic and interaction claims (protein binding percentage/albumin binding, warfarin/digoxin displacement and resulting bleeding/toxicity) are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit claims to the supplied label content: use the labeled indications and endpoints from SECTION 1.1/1.2, and for interactions reference the label-described increased myopathy risk with specific drug classes/strong CYP3A4 inhibitors and related dose cautions (SECTION 5.1, 7, 2.6). Remove or qualify the unsupported protein-binding displacement and patent/generic availability statements.